Retinopathy of prematurity-promising newer modalities of treatment

Indian Pediatrics

Volumn 49, Issue 2, 2012, Pages 139-143

  Niranjan, H S ^a   Benakappa, Naveen ^a   Bharath Kumar Reddy, K R ^a   Shivananda, ^a   Vasudeva Kamath, M ^a  

^a INDIRA GANDHI INSTITUTE OF CHILD HEALTH   (India)

Author keywords

Anti VEGF; Gene therapy; GSCF; IGF; JNK1 inhibitor; Retinopathy

Indexed keywords

ADENOVIRUS VECTOR; BEVACIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; MECASERMIN RINFABATE; PEGAPTANIB; RANIBIZUMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT SOMATOMEDIN C; RINFABATE; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CONFERENCE PAPER; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ENOS GENE; GENE; GENE THERAPY; HUMAN; INJECTION SITE INFECTION; INJECTION SITE REACTION; LASER SURGERY; LOW DRUG DOSE; MEDICAL RESEARCH; NDP GENE; NONHUMAN; PATHOGENESIS; PUBLICATION; RETINA MACULA AGE RELATED DEGENERATION; RETROLENTAL FIBROPLASIA; VEGF GENE; VIRAL GENE DELIVERY SYSTEM; VITRECTOMY;

GENE THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MITOGEN-ACTIVATED PROTEIN KINASE 8; RETINOPATHY OF PREMATURITY; SOMATOMEDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863085968     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-012-0028-2     Document Type: Conference Paper

References (43)

1. Kim TI, Sohn J, Pi SY, Yoon YH. Postnatal risk factors of retinopathy of prematurity. Paediatr Perinat Epidemiol. 2004;18:130-4.
2. Vinekar A, Dogra MR, Sangtam T, Narang A, Gupta A. Retinopathy of prematurity in Asian Indian babies weighing greater than 1250 grams at birth: ten year data from a tertiary care centre in a developing country. Indian J Ophthalmol. 2007;55:331-6.
3. Chong LP, Machemer R, de Juan E Jr. Vitrectomy for advanced stage of ROP. Am J Ophthalmol. 1986;102:710-16.
4. Cryotherapy for retinopathy of prematurity cooperative group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988;106:471-9.
5. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial for cryotherapy for retinopathy of prematurity: one-year outcome-structure and function. Arch Ophthalmol. 1990;108:1408-16.
6. Laser ROP Study Group. Laser therapy for retinopathy of prematurity. Arch Ophthalmol. 1994;112 2:154-6.
7. Kretzer FL, Hittner HM. Retinopathy of prematurity: clinical implications of retinal development. Arch Dis Child. 1988;63:1151-67.
8. Ashton N. Oxygen and the retinal blood vessels. Trans Ophthalmol Soc UK. 1980;100:359-62.
9. Csak K, Szabo V, Szabo A, Vannay A. Pathogenesis and genetic basis for retinopathy of prematurity. Front Biosci. 2006;11:908-20.
10. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-39.
11. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
12. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738-47.
13. Shalaby F, Rossant J, Yamaguchi TP, Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-6.
14. Himeno W, Akagi T, Furui J. Increased angiogenic growth factor in cyanotic congenital heart disease. Pediatr Cardiol. 2003;24:127-32.
15. Lassus P, Ristimaki A, Ylikorkala O, Viinikka L, Andersson S. Vascular endothelial growth factor in human preterm lung. Am J Respir Crit Care Med. 1999;159:1429-33.
16. Suzuma K, Takagi H, Otani A, Suzuma I, Honda Y. Increased expression of KDR/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization. Microvasc Res. 1998;56:183-91.
17. McLeod DS, Taomoto M, Cao J, Zhu Z, Witte L, Lutty GA. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2002; 43:474-82.
18. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000;156:1337-44.
19. Umeda N, Ozaki H, Hayashi H. Colocalization of Tie2, angiopoietin 2 and vascular endothelial growth factor in fibrovascular membrane from patients with retinopathy of prematurity. Ophthalm Res. 2003;35:217-23.
20. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;14:S140-4.
21. Avery RL, Pieramici DJ, Rabena MD. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-72.
22. Avery RL, Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology. 2006;113:363-72.
23. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovasculariztion after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:155-8.
24. Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450-5.
25. Mintz-Hittner H, Kuffel R. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831-8.
26. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-9.
27. Velpandian T, Sharma C, Garg SP, Mandal S, Ghose S. Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries. Indian J Ophthalmol. 2007;55:488-90.
28. Darlow BA, Gilbert C, Quinn GE. Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity. Br J Ophthalmol. 2009;93:986.
29. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hård AL, Liu J, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. PNAS. 2001;98:5804-8.
30. Hellstrom A, Engstrom E, Hard AL, Albertsson-Wikland K, Carlsson B, Niklasson A, et al. Postnatal serum insulinlike growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003;112:1016-20.
31. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Sjodell L, Liu J, et al. Low IGF-I suppresses VEGF survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA. 2001;98:5804-8.
32. Hellstrom A, Carlsson B, Niklasson A, Segestam K, Boguszewski M, Laron Z, et al. IGFI - is critical for normal vascularization of the human retina; J Clin Endocrinol Metabo. 2002;87:3413-6.
33. Löfqvist C, Niklasson A, Engström E, Friberg LE, Camacho-Hübner C, Ley D, et al. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants; Pediatr Res. 2009;65:574-9.
34. Kojima H, Otani A, Oishi A, Makiyama Y, Nakagawa S, Yoshimura N. Granulocyte colony-stimulating factor attenuates oxidative stress-induced apoptosis in vascular endothelial cells and exhibits functional and morphologic protective effect in oxygen-induced retinopathy; Blood. 2011;117:1091-1100.
35. Bhola R, Purkiss T, Hunter S, Stewart D, Rychwalski PJ. Effect of granulocyte colony-stimulating factor on the incidence of threshold retinopathy of prematurity. J AAPOS. 2009;13:450-3.
36. Karin M, Gallagher E. From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life. 2005:57:283-95.
37. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem. 2000;275:26484-91.
38. Guma M, Rius J, Karen X. Duong-Polk, Haddad GG, Lindsey JD, et al. Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. PNAS. 2009;106;8760-5.
39. Guma M, Rius J, Duong-Polk KX, Haddad GG, Lindsey JD, Karin M. Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc Natl Acad Sci USA. 2009;106:8760-5.
40. Kwinta P, Pietrzyk JJ. Retinopathy of prematurity: is genetic predisposition an important risk factor? Exp Rev Ophthalmol. 2007;2:275-83.
41. Holmström G, van Wijngaarden P, Coster DJ, Williams KA. Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies. Br J Ophthalmol. 2007;91:1704-8.
42. Rolling F. Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives. Gene Therapy. 2004;11:S26-2.
43. Chower S. Gene therapy for retinopathy of prematurity: the eye is a window to the future. Br J Ophthalmol. 2001;85:891-3.